Advertisement

Prognostication and Risk Assessment

  • Luis A. Kluth
  • Bernard H. Bochner
  • Shahrokh F. ShariatEmail author
Chapter

Abstract

Prognostication and risk assessment are essential for treatment decision-making, patient counseling, and determination of eligibility for clinical trials. More than most other malignancies, urothelial carcinoma of the bladder cancer (UCB) is a highly aggressive and heterogeneous disease with high prevalence and disease recurrence rates. In patients with non-muscle invasive bladder cancer (NMIBC), prognosticators of outcomes and predictive tools providing useful risk estimates in UCB patients could help in the decision-making regarding follow-up scheduling, administration of intravesical instillation therapies, and/or early radical cystectomy (RC). In patients with muscle-invasive bladder cancer (MICB) who underwent RC, an accurate prediction of the presence of lymph node metastasis and the probability of disease recurrence is essential for selecting patients who might benefit from adjuvant systemic chemotherapy. Here, we aimed to give an overview of the prognostic factors and currently available prediction tools associated with UCB outcomes in NMIBC, MIBC, and metastatic UCB.

Keywords

Urothelial carcinoma of the bladder Bladder cancer Prognosis Outcome Disease recurrence Disease progression Survival Model Nomogram Risk stratification 

References

  1. 1.
    Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 Pt 1):2186–90. quiz 2435.PubMedGoogle Scholar
  2. 2.
    Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2012;62(3):523–33.PubMedGoogle Scholar
  3. 3.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–4.PubMedGoogle Scholar
  4. 4.
    Bochner BH, Kattan MW, Vora KC. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol. 2006;24(24):3967–72.PubMedGoogle Scholar
  5. 5.
    Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, et al. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176(4 Pt 1):1354–61. discussion 1361–1352.PubMedGoogle Scholar
  6. 6.
    Shariat SF, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, et al. Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res. 2006;12(22):6663–76.PubMedGoogle Scholar
  7. 7.
    Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, et al. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. Br J Cancer. 2012;107(11):1826–32.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Shariat SF, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, et al. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. Eur Urol. 2013;63(2):371–8.PubMedGoogle Scholar
  9. 9.
    Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol. 2009;5(10):1555–84.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Shariat SF, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? BJU Int. 2009;103(4):492–5. discussion 495–497.PubMedGoogle Scholar
  11. 11.
    Kattan MW. Nomograms. Introduction. Semin Urol Oncol. 2002;20(2):79–81.PubMedGoogle Scholar
  12. 12.
    Kattan MW. J Urol. 2003;170(6 Pt 2):S6–9. discussion S10.PubMedGoogle Scholar
  13. 13.
    Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003;13(2):111–6.PubMedGoogle Scholar
  14. 14.
    Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–203.PubMedGoogle Scholar
  15. 15.
    Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, et al. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. J Urol. 2013;190(2):480–6.PubMedGoogle Scholar
  16. 16.
    Saint F, Salomon L, Quintela R, Cicco A, Hoznek A, Abbou CC, Chopin DK. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guerin (BCG) immunotherapy exist? Analysis of a quarter century of literature. Eur Urol. 2003;43(4):351–60. discussion 360–351.PubMedGoogle Scholar
  17. 17.
    Joudi FN, Smith BJ, O’Donnell MA, Konety BR. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol. 2006;175(5):1634–9. discussion 1639–1640.PubMedGoogle Scholar
  18. 18.
    Herr HW. Age and outcome of superficial bladder cancer treated with bacille Calmette-Guerin therapy. Urology. 2007;70(1):65–8.PubMedGoogle Scholar
  19. 19.
    Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int. 2010;105(3):300–8.PubMedGoogle Scholar
  20. 20.
    Rosevear HM, Lightfoot AJ, Birusingh KK, Maymi JL, Nepple KG, O’Donnell MA. Factors affecting response to bacillus Calmette-Guerin plus interferon for urothelial carcinoma in situ. J Urol. 2011;186(3):817–23.PubMedGoogle Scholar
  21. 21.
    Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013;63(5):823–9.PubMedGoogle Scholar
  22. 22.
    Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB. Ethnic differences in bladder cancer survival. Urology. 2011;78(3):544–9.PubMedCentralPubMedGoogle Scholar
  23. 23.
    Puente D, Malats N, Cecchini L, Tardon A, Garcia-Closas R, Serra C, Carrato A, Sala M, Boixeda R, Dosemeci M, et al. Gender-related differences in clinical and pathological characteristics and therapy of bladder cancer. Eur Urol. 2003;43(1):53–62.PubMedGoogle Scholar
  24. 24.
    Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Roupret M, Becker A, Comploj E, Pycha A, Holmang S, et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol. 2013;31(5):1029–36.PubMedGoogle Scholar
  25. 25.
    Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–75. discussion 475–467.PubMedGoogle Scholar
  26. 26.
    Palou J, Sylvester RJ, Faba OR, Parada R, Pena JA, Algaba F, Villavicencio H. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guerin. Eur Urol. 2012;62(1):118–25.PubMedGoogle Scholar
  27. 27.
    Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306(7):737–45.PubMedCentralPubMedGoogle Scholar
  28. 28.
    Lammers RJ, Witjes WP, Hendricksen K, Caris CT, Janzing-Pastors MH, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011;60(4):713–20.PubMedGoogle Scholar
  29. 29.
    Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, Dahlem R, Shariat SF. Smoking reduces the efficacy of intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer. Eur Urol. 2012;62(6):1204–6.PubMedGoogle Scholar
  30. 30.
    Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol. 2013;63(4):724–32.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012;188(6):2120–7.PubMedGoogle Scholar
  32. 32.
    Martinez-Pineiro JA, Flores N, Isorna S, Solsona E, Sebastian JL, Pertusa C, Rioja LA, Martinez-Pineiro L, Vela R, Camacho JE, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int. 2002;89(7):671–80.PubMedGoogle Scholar
  33. 33.
    Alkhateeb SS, Van Rhijn BW, Finelli A, van der Kwast T, Evans A, Hanna S, Vajpeyi R, Fleshner NE, Jewett MA, Zlotta AR. Nonprimary pT1 nonmuscle invasive bladder cancer treated with bacillus Calmette-Guerin is associated with higher risk of progression compared to primary T1 tumors. J Urol. 2010;184(1):81–6.PubMedGoogle Scholar
  34. 34.
    Thomas F, Noon AP, Rubin N, Goepel JR, Catto JW. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer. Eur Urol. 2013;63(1):145–54.PubMedGoogle Scholar
  35. 35.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009;27(2):155–9.PubMedCentralPubMedGoogle Scholar
  36. 36.
    Denzinger S, Otto W, Fritsche HM, Roessler W, Wieland WF, Hartmann A, Burger M. Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients. Int J Urol. 2007;14(11):995–9. discussion 999.PubMedGoogle Scholar
  37. 37.
    Fernandez-Gomez J, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Hernandez R, Madero R, Ojea A, Pertusa C, Rodriguez-Molina J, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol. 2008;53(5):992–1001.PubMedGoogle Scholar
  38. 38.
    Amin MB, McKenney JK, Paner GP, Hansel DE, Grignon DJ, Montironi R, Lin O, Jorda M, Jenkins LC, Soloway M, et al. ICUD-EAU International Consultation on Bladder Cancer 2012: pathology. Eur Urol. 2013;63(1):16–35.PubMedGoogle Scholar
  39. 39.
    Chang WC, Chang YH, Pan CC. Prognostic significance in substaging of T1 urinary bladder urothelial carcinoma on transurethral resection. Am J Surg Pathol. 2012;36(3):454–61.PubMedGoogle Scholar
  40. 40.
    Orsola A, Trias I, Raventos CX, Espanol I, Cecchini L, Bucar S, Salinas D, Orsola I. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol. 2005;48(2):231–8. discussion 238.PubMedGoogle Scholar
  41. 41.
    van Rhijn BW, van der Kwast TH, Alkhateeb SS, Fleshner NE, van Leenders GJ, Bostrom PJ, van der Aa MN, Kakiashvili DM, Bangma CH, Jewett MA, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol. 2012;61(2):378–84.PubMedGoogle Scholar
  42. 42.
    Pan CC, Chang YH, Chen KK, Yu HJ, Sun CH, Ho DM. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1,515 cases. Am J Clin Pathol. 2010;133(5):788–95.PubMedGoogle Scholar
  43. 43.
    Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH, Steyerberg EC, Stoehr R, Kirkels WJ, Denzinger S, Wild PJ, et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol. 2008;54(4):835–43.PubMedGoogle Scholar
  44. 44.
    MacLennan GT, Kirkali Z, Cheng L. Histologic grading of noninvasive papillary urothelial neoplasms. Eur Urol. 2007;51(4):889–97. discussion 897–888.PubMedGoogle Scholar
  45. 45.
    May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, Gilfrich C, Borchardt R, Hoschke B, Kaufmann O, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010;57(5):850–8.PubMedGoogle Scholar
  46. 46.
    van Rhijn BW, van Leenders GJ, Ooms BC, Kirkels WJ, Zlotta AR, Boeve ER, Jobsis AC, van der Kwast TH. The pathologist’s mean grade is constant and individualizes the prognostic value of bladder cancer grading. Eur Urol. 2010;57(6):1052–7.PubMedGoogle Scholar
  47. 47.
    Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol. 2004;46(2):170–6.PubMedGoogle Scholar
  48. 48.
    Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54(2):303–14.PubMedGoogle Scholar
  49. 49.
    Kakiashvili DM, van Rhijn BW, Trottier G, Jewett MA, Fleshner NE, Finelli A, Azuero J, Bangma CH, Vajpeyi R, Alkhateeb S, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guerin treatment. BJU Int. 2011;107(4):540–6.PubMedGoogle Scholar
  50. 50.
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB, Beck TM, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124–9.PubMedGoogle Scholar
  51. 51.
    Kunju LP, You L, Zhang Y, Daignault S, Montie JE, Lee CT. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens. J Urol. 2008;180(5):1928–32. discussion 1932.PubMedGoogle Scholar
  52. 52.
    Cho KS, Seo HK, Joung JY, Park WS, Ro JY, Han KS, Chung J, Lee KH. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer. J Urol. 2009;182(6):2625–30.PubMedGoogle Scholar
  53. 53.
    Streeper NM, Simons CM, Konety BR, Muirhead DM, Williams RD, O’Donnell MA, Joudi FN. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer. BJU Int. 2009;103(4):475–9.PubMedGoogle Scholar
  54. 54.
    Resnick MJ, Bergey M, Magerfleisch L, Tomaszewski JE, Malkowicz SB, Guzzo TJ. Longitudinal evaluation of the concordance and prognostic value of lymphovascular invasion in transurethral resection and radical cystectomy specimens. BJU Int. 2011;107(1):46–52.PubMedGoogle Scholar
  55. 55.
    Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, et al. Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. BJU Int. 2013;111(3):404–11.PubMedGoogle Scholar
  56. 56.
    Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol. 2006;175(3 Pt 1):881–5.PubMedGoogle Scholar
  57. 57.
    Amin A, Epstein JI. Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases. Hum Pathol. 2012;43(12):2124–8.PubMedGoogle Scholar
  58. 58.
    Gaya JM, Palou J, Algaba F, Arce J, Rodriguez-Faba O, Villavicencio H. The case for conservative management in the treatment of patients with non-muscle-invasive micropapillary bladder carcinoma without carcinoma in situ. Can J Urol. 2010;17(5):5370–6.PubMedGoogle Scholar
  59. 59.
    Chang SS, Hassan JM, Cookson MS, Wells N, Smith Jr JA. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003;170(4 Pt 1):1085–7.PubMedGoogle Scholar
  60. 60.
    Lee CT, Madii R, Daignault S, Dunn RL, Zhang Y, Montie JE, Wood Jr DP. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006;175(4):1262–7. discussion 1267.PubMedGoogle Scholar
  61. 61.
    Nielsen ME, Palapattu GS, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, Shariat SF. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int. 2007;100(5):1015–20.PubMedGoogle Scholar
  62. 62.
    Hautmann RE, Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy? J Urol. 1998;159(6):1845–50.PubMedGoogle Scholar
  63. 63.
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol. 2000;164(3 Pt 1):680–4.PubMedGoogle Scholar
  64. 64.
    Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Ojea A, Portillo J, Montesinos M, Gonzalez M, Pertusa C, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: external validation of the EORTC risk tables. Eur Urol. 2011;60(3):423–30.PubMedGoogle Scholar
  65. 65.
    Hernandez V, De La Pena E, Martin MD, Blazquez C, Diaz FJ, Llorente C. External validation and applicability of the EORTC risk tables for non-muscle-invasive bladder cancer. World J Urol. 2011;29(4):409–14.PubMedGoogle Scholar
  66. 66.
    Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. Br J Cancer. 2013;109(6):1460–6.PubMedCentralPubMedGoogle Scholar
  67. 67.
    Shariat SF, Zippe C, Ludecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, et al. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. J Urol. 2005;173(5):1518–25.PubMedGoogle Scholar
  68. 68.
    Shariat SF, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol. 2007;51(1):137–49. discussion 149–151.PubMedGoogle Scholar
  69. 69.
    Karakiewicz PI, Shariat SF, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, et al. Precystectomy nomogram for prediction of advanced bladder cancer stage. Eur Urol. 2006;50(6):1254–60. discussion 1261–1252.PubMedGoogle Scholar
  70. 70.
    Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, et al. Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol. 2012;61(2):237–42.PubMedGoogle Scholar
  71. 71.
    Shariat SF, Karam JA, Lerner SP. Molecular markers in bladder cancer. Curr Opin Urol. 2008;18(1):1–8.PubMedGoogle Scholar
  72. 72.
    Soulie M, Straub M, Game X, Seguin P, De Petriconi R, Plante P, Hautmann RE. A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 2002;167(3):1325–8.PubMedGoogle Scholar
  73. 73.
    Chang SS, Alberts G, Cookson MS, Smith Jr JA. Radical cystectomy is safe in elderly patients at high risk. J Urol. 2001;166(3):938–41.PubMedGoogle Scholar
  74. 74.
    Thrasher JB, Frazier HA, Robertson JE, Dodge RK, Paulson DF. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1994;73(6):1708–15.PubMedGoogle Scholar
  75. 75.
    Clark PE, Stein JP, Groshen SG, Cai J, Miranda G, Lieskovsky G, Skinner DG. Radical cystectomy in the elderly: comparison of survival between younger and older patients. Cancer. 2005;103(3):546–52.PubMedGoogle Scholar
  76. 76.
    Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, Shariat SF. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol. 2011;29(4):457–63.PubMedGoogle Scholar
  77. 77.
    Boorjian SA, Zhu F, Herr HW. The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder. BJU Int. 2010;106(3):357–61.PubMedGoogle Scholar
  78. 78.
    McGrath M, Michaud DS, De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol. 2006;163(3):236–44.PubMedGoogle Scholar
  79. 79.
    Donsky H, Coyle S, Scosyrev E, Messing EM. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol Oncol. 2014;32(1):40.e23–31.Google Scholar
  80. 80.
    Scosyrev E, Golijanin D, Wu G, Messing E. The burden of bladder cancer in men and women: analysis of the years of life lost. BJU Int. 2012;109(1):57–62.PubMedGoogle Scholar
  81. 81.
    Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, Sonpavde G, Ayala GE, Younes M, Lerner SP. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer. 2006;106(12):2610–6.PubMedGoogle Scholar
  82. 82.
    Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, Scherr DS. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology. 2004;64(2):383–8.PubMedGoogle Scholar
  83. 83.
    May M, Bastian PJ, Brookman-May S, Fritsche HM, Tilki D, Otto W, Bolenz C, Gilfrich C, Trojan L, Herrmann E, et al. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a. Urol Oncol. 2013;31(7):1141–7.PubMedGoogle Scholar
  84. 84.
    Otto W, May M, Fritsche HM, Dragun D, Aziz A, Gierth M, Trojan L, Herrmann E, Moritz R, Ellinger J, et al. Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicenter study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med. 2012;9(6):481–9.PubMedGoogle Scholar
  85. 85.
    Zhuang YH, Blauer M, Tammela T, Tuohimaa P. Immunodetection of androgen receptor in human urinary bladder cancer. Histopathology. 1997;30(6):556–62.PubMedGoogle Scholar
  86. 86.
    Siegrist T, Savage C, Shabsigh A, Cronin A, Donat SM. Analysis of gender differences in early perioperative complications following radical cystectomy at a tertiary cancer center using a standardized reporting methodology. Urol Oncol. 2010;28(1):112–7.PubMedGoogle Scholar
  87. 87.
    Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, et al. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011;77(3):660–6.PubMedGoogle Scholar
  88. 88.
    Taub DA, Hollenbeck BK, Cooper KL, Dunn RL, Miller DC, Taylor JM, Wei JT. Racial disparities in resource utilization for cystectomy. Urology. 2006;67(2):288–93.PubMedGoogle Scholar
  89. 89.
    Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA. Gender differences in stage distribution of bladder cancer. Urology. 2000;55(3):368–71.PubMedGoogle Scholar
  90. 90.
    Johnson EK, Daignault S, Zhang Y, Lee CT. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008;72(3):498–502. discussion 502–493.PubMedGoogle Scholar
  91. 91.
    Kiemeney LA, Coebergh JW, Koper NP, van der Heijden LH, Pauwels RP, Schapers RF, Verbeek AL. Bladder cancer incidence and survival in the south-eastern part of The Netherlands, 1975–1989. Eur J Cancer. 1994;30A(8):1134–7.PubMedGoogle Scholar
  92. 92.
    Micheli A, Mariotto A, Giorgi Rossi A, Gatta G, Muti P. The prognostic role of gender in survival of adult cancer patients. EUROCARE Working Group. Eur J Cancer. 1998;34(14 Spec No):2271–8.PubMedGoogle Scholar
  93. 93.
    Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, Kiemeney LA. Gender differences in stage-adjusted bladder cancer survival. Urology. 2000;55(6):876–80.PubMedGoogle Scholar
  94. 94.
    Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1996;78(7):1505–13.PubMedGoogle Scholar
  95. 95.
    Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH, Thapa P, Frank I. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol. 2013;190(1):55–60.PubMedGoogle Scholar
  96. 96.
    Mayr R, May M, Martini T, Lodde M, Comploj E, Pycha A, Strobel J, Denzinger S, Otto W, Wieland W, et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur Urol. 2012;62(4):662–70.PubMedGoogle Scholar
  97. 97.
    Gakis G, Todenhofer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011;108(11):1800–5.PubMedGoogle Scholar
  98. 98.
    Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev. 2006;15(2):381–4.PubMedGoogle Scholar
  99. 99.
    Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, Kobayashi T, Kawakami S, Kihara K. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008;101(8):978–81.PubMedGoogle Scholar
  100. 100.
    Ripamonti CI, Farina G, Garassino MC. Predictive models in palliative care. Cancer. 2009;115(13 Suppl):3128–34.PubMedGoogle Scholar
  101. 101.
    Inoue K, Kohashikawa K, Suzuki S, Shimada M, Yoshida H. Prognostic significance of thrombocytosis in renal cell carcinoma patients. Int J Urol. 2004;11(6):364–7.PubMedGoogle Scholar
  102. 102.
    Todenhofer T, Renninger M, Schwentner C, Stenzl A, Gakis G. A new prognostic model for cancer-specific survival after radical cystectomy including pretreatment thrombocytosis and standard pathological risk factors. BJU Int. 2012;110(11 Pt B):E533–40.PubMedGoogle Scholar
  103. 103.
    Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134(1):36–42.PubMedGoogle Scholar
  104. 104.
    Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson Jr CJ, Aghazadeh M, Smith Jr JA, et al. Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer. J Urol. 2011;185(1):90–6.PubMedCentralPubMedGoogle Scholar
  105. 105.
    Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013;111(2):249–55.PubMedGoogle Scholar
  106. 106.
    Hafron J, Mitra N, Dalbagni G, Bochner B, Herr H, Donat SM. Does body mass index affect survival of patients undergoing radical or partial cystectomy for bladder cancer? J Urol. 2005;173(5):1513–7.PubMedGoogle Scholar
  107. 107.
    Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, et al. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. Eur Urol. 2013;64(3):456–64.PubMedGoogle Scholar
  108. 108.
    Sturgeon SR, Hartge P, Silverman DT, Kantor AF, Linehan WM, Lynch C, Hoover RN. Associations between bladder cancer risk factors and tumor stage and grade at diagnosis. Epidemiology. 1994;5(2):218–25.PubMedGoogle Scholar
  109. 109.
    Jiang X, Castelao JE, Yuan JM, Stern MC, Conti DV, Cortessis VK, Pike MC, Gago-Dominguez M. Cigarette smoking and subtypes of bladder cancer. Int J Cancer. 2012;130(4):896–901.PubMedCentralPubMedGoogle Scholar
  110. 110.
    Chen CH, Shun CT, Huang KH, Huang CY, Tsai YC, Yu HJ, Pu YS. Stopping smoking might reduce tumour recurrence in nonmuscle-invasive bladder cancer. BJU Int. 2007;100(2):281–6. discussion 286.PubMedGoogle Scholar
  111. 111.
    Roth B, Wissmeyer MP, Zehnder P, Birkhauser FD, Thalmann GN, Krause TM, Studer UE. A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder. Eur Urol. 2010;57(2):205–11.PubMedGoogle Scholar
  112. 112.
    Jensen JB, Ulhoi BP, Jensen KM. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery. BJU Int. 2010;106(2):199–205.PubMedGoogle Scholar
  113. 113.
    Leissner J, Ghoneim MA, Abol-Enein H, Thuroff JW, Franzaring L, Fisch M, Schulze H, Managadze G, Allhoff EP, Managadze G, el-Baz MA, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol. 2004;171(1):139–44.PubMedGoogle Scholar
  114. 114.
    Wright JL, Lin DW, Porter MP. The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomy. Cancer. 2008;112(11):2401–8.PubMedGoogle Scholar
  115. 115.
    May M, Herrmann E, Bolenz C, Brookman-May S, Tiemann A, Moritz R, Fritsche HM, Burger M, Trojan L, Michel MS, et al. Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol. 2011;18(7):2018–25.PubMedGoogle Scholar
  116. 116.
    Stein JP. The role of lymphadenectomy in patients undergoing radical cystectomy for bladder cancer. Curr Oncol Rep. 2007;9(3):213–21.PubMedGoogle Scholar
  117. 117.
    Herr HW, Faulkner JR, Grossman HB, Natale RB, deVere White R, Sarosdy MF, Crawford ED. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol. 2004;22(14):2781–9.PubMedGoogle Scholar
  118. 118.
    Poulsen AL, Horn T, Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol. 1998;160(6 Pt 1):2015–9. discussion 2020.PubMedGoogle Scholar
  119. 119.
    Herr HW, Bochner BH, Dalbagni G, Donat SM, Reuter VE, Bajorin DF. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol. 2002;167(3):1295–8.PubMedGoogle Scholar
  120. 120.
    Lerner SP, Skinner DG, Lieskovsky G, Boyd SD, Groshen SL, Ziogas A, Skinner E, Nichols P, Hopwood B. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol. 1993;149(4):758–64. discussion 764–755.PubMedGoogle Scholar
  121. 121.
    Koppie TM, Vickers AJ, Vora K, Dalbagni G, Bochner BH. Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed? Cancer. 2006;107(10):2368–74.PubMedGoogle Scholar
  122. 122.
    Zehnder P, Studer UE, Skinner EC, Dorin RP, Cai J, Roth B, Miranda G, Birkhauser F, Stein J, Burkhard FC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol. 2011;186(4):1261–8.PubMedGoogle Scholar
  123. 123.
    Konety BR, Joslyn SA, O’Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol. 2003;169(3):946–50.PubMedGoogle Scholar
  124. 124.
    Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–75.PubMedGoogle Scholar
  125. 125.
    Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, et al. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? World J Urol. 2012;30(6):807–14.PubMedGoogle Scholar
  126. 126.
    Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176(6 Pt 1):2414–22. discussion 2422.PubMedGoogle Scholar
  127. 127.
    Epstein JI, Amin MB, Reuter VR, Mostofi FK. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 1998;22(12):1435–48.PubMedGoogle Scholar
  128. 128.
    Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, Kiemeney L, Kriegmair M, Montironi R, Murphy WM, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.PubMedGoogle Scholar
  129. 129.
    Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, Sjoberg D, Dalbagni G, Bochner BH. Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity. Eur Urol. 2012;61(5):1025–30.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Herr HW. Surgical factors in the treatment of superficial and invasive bladder cancer. Urol Clin North Am. 2005;32(2):157–64.PubMedGoogle Scholar
  131. 131.
    Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, et al. Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy. Ann Surg Oncol. 2013;20(3):1027–34.PubMedGoogle Scholar
  132. 132.
    Fung CY, Shipley WU, Young RH, Griffin PP, Convery KM, Kaufman DS, Althausen AF, Heney NM, Prout Jr GR. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol. 1991;9(9):1533–42.PubMedGoogle Scholar
  133. 133.
    Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Scherer BG, Nehra A, Zincke H, Bostwick DG. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer. 2000;88(10):2326–32.PubMedGoogle Scholar
  134. 134.
    Alitalo K, Mohla S, Ruoslahti E. Lymphangiogenesis and cancer: meeting report. Cancer Res. 2004;64(24):9225–9.PubMedGoogle Scholar
  135. 135.
    Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002;296(5574):1883–6.PubMedGoogle Scholar
  136. 136.
    Algaba F. Lymphovascular invasion as a prognostic tool for advanced bladder cancer. Curr Opin Urol. 2006;16(5):367–71.PubMedGoogle Scholar
  137. 137.
    Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, et al. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int. 2010;105(10):1402–12.PubMedGoogle Scholar
  138. 138.
    Fritsche HM, May M, Denzinger S, Otto W, Siegert S, Giedl C, Giedl J, Eder F, Agaimy A, Novotny V, et al. Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol. 2013;63(4):739–44.PubMedGoogle Scholar
  139. 139.
    Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005;23(27):6533–9.PubMedGoogle Scholar
  140. 140.
    Tilki D, Shariat SF, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. BJU Int. 2013;111(8):1215–21.PubMedGoogle Scholar
  141. 141.
    Quek ML, Stein JP, Nichols PW, Cai J, Miranda G, Groshen S, Daneshmand S, Skinner EC, Skinner DG. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol. 2005;174(1):103–6.PubMedGoogle Scholar
  142. 142.
    Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, et al. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol. 2006;175(6):2048–53. discussion 2053.PubMedGoogle Scholar
  143. 143.
    Mitra AP, Bartsch CC, Bartsch Jr G, Miranda G, Skinner EC, Daneshmand S. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis. Urol Oncol. 2014;32(2):117–27.PubMedGoogle Scholar
  144. 144.
    Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, Boorjian SA. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012;188(2):405–9.PubMedGoogle Scholar
  145. 145.
    Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer. 2013;49(8):1889–97.PubMedGoogle Scholar
  146. 146.
    Linder BJ, Frank I, Cheville JC, Thompson RH, Thapa P, Tarrell RF, Boorjian SA. Outcomes following radical cystectomy for nested variant of urothelial carcinoma: a matched cohort analysis. J Urol. 2013;189(5):1670–5.PubMedGoogle Scholar
  147. 147.
    Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, Scherr DS, Shariat SF. Immunohistochemical biomarkers for bladder cancer prognosis. Int J Urol. 2011;18(9):616–29.PubMedGoogle Scholar
  148. 148.
    Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307–10.PubMedGoogle Scholar
  149. 149.
    Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol. 2004;22(6):1007–13.PubMedGoogle Scholar
  150. 150.
    Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 2005;6(9):678–86.PubMedGoogle Scholar
  151. 151.
    Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, et al. p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol. 2009;182(3):907–13.PubMedGoogle Scholar
  152. 152.
    Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–24.PubMedGoogle Scholar
  153. 153.
    Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007;20(4):445–59.PubMedGoogle Scholar
  154. 154.
    Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, et al. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010;105(4):489–95.PubMedGoogle Scholar
  155. 155.
    Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010;183(1):68–75.PubMedGoogle Scholar
  156. 156.
    Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, de The H, Sibony M, Denoux Y, Molinie V, Herault A, et al. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One. 2012;7(12):e48993.PubMedCentralPubMedGoogle Scholar
  157. 157.
    Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29(25):3443–9.PubMedCentralPubMedGoogle Scholar
  158. 158.
    Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol. 2009;182(1):78–84. discussion 84.PubMedGoogle Scholar
  159. 159.
    Park J, Song C, Shin E, Hong JH, Kim CS, Ahn H. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy? Urol Oncol. 2013;31(6):849–56.PubMedGoogle Scholar
  160. 160.
    Lenz P, Pfeiffer R, Baris D, Schned AR, Takikita M, Poscablo MC, Schwenn M, Johnson A, Jones M, Kida M, et al. Cell-cycle control in urothelial carcinoma: large-scale tissue array analysis of tumor tissue from Maine and Vermont. Cancer Epidemiol Biomarkers Prev. 2012;21(9):1555–64.PubMedCentralPubMedGoogle Scholar
  161. 161.
    Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res. 2006;12(24):7369–73.PubMedGoogle Scholar
  162. 162.
    Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Muller SC, et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst. 2009;101(2):114–9.PubMedGoogle Scholar
  163. 163.
    Behnsawy HM, Miyake H, Abdalla MA, Sayed MA, Ahmed AE, Fujisawa M. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection. Urol Oncol. 2011;29(5):495–501.PubMedGoogle Scholar
  164. 164.
    Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol. 2000;36(1):3–7.PubMedGoogle Scholar
  165. 165.
    Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, et al. Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer. 2013;119(4):756–65.PubMedCentralPubMedGoogle Scholar
  166. 166.
    Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol. 2006;37(12):1568–76.PubMedGoogle Scholar
  167. 167.
    Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol. 1999;155(4):1129–36.PubMedCentralPubMedGoogle Scholar
  168. 168.
    Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J Urol. 2008;26(1):59–65.PubMedGoogle Scholar
  169. 169.
    Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathol Int. 2005;55(3):122–9.PubMedGoogle Scholar
  170. 170.
    Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med. 2000;343(19):1418–20.PubMedGoogle Scholar
  171. 171.
    Giannopoulou I, Nakopoulou L, Zervas A, Lazaris AC, Stravodimos C, Giannopoulos A, Davaris PS. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res. 2002;30(5):342–5.PubMedGoogle Scholar
  172. 172.
    Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, Shariat SF. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007;8(2):128–36.PubMedGoogle Scholar
  173. 173.
    Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581–9.PubMedGoogle Scholar
  174. 174.
    Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW, Gunnewiek JM, de Kok JB. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem. 2004;50(8):1425–8.PubMedGoogle Scholar
  175. 175.
    Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol. 2004;171(2 Pt 1):626–30.PubMedGoogle Scholar
  176. 176.
    Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Alterieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA. 2001;285(3):324–8.PubMedGoogle Scholar
  177. 177.
    Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer. 2007;109(6):1106–13.PubMedGoogle Scholar
  178. 178.
    Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res. 2009;15(22):7012–9.PubMedGoogle Scholar
  179. 179.
    Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR, Sun TT, Altieri DC. A survivin gene signature predicts aggressive tumor behavior. Cancer Res. 2005;65(9):3531–4.PubMedGoogle Scholar
  180. 180.
    Xi RC, Sheng YR, Chen WH, Sheng L, Gang JJ, Tong Z, Shan Z, Ying GH, Dong LC. Expression of survivin and livin predicts early recurrence in non-muscle invasive bladder cancer. J Surg Oncol. 2013;107(5):550–4.PubMedGoogle Scholar
  181. 181.
    Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, Shariat SF. Tissue-based molecular markers for bladder cancer. Minerva Urol Nefrol. 2010;62(3):241–58.PubMedGoogle Scholar
  182. 182.
    Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG, Nichols PW. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87(21):1603–12.PubMedGoogle Scholar
  183. 183.
    Jaeger TM, Weidner N, Chew K, Moore DH, Kerschmann RL, Waldman FM, Carroll PR. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer. J Urol. 1995;154(1):69–71.PubMedGoogle Scholar
  184. 184.
    Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 2000;6(12):4866–73.PubMedGoogle Scholar
  185. 185.
    Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 2010;183(5):1744–50.PubMedGoogle Scholar
  186. 186.
    Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S, Dunn M, Nichols PW, Taylor CR, Skinner DG, et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst. 1997;89(3):219–27.PubMedGoogle Scholar
  187. 187.
    Shariat SF, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, et al. Combination of cell cycle regulating bio-markers improves prognosis in patients with organ-confined urothelial carcinoma at radical cystectomy. J Urol. 2008;179(4):578.Google Scholar
  188. 188.
    Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008;112(2):315–25.PubMedGoogle Scholar
  189. 189.
    Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol. 2013;64(3):465–71.PubMedGoogle Scholar
  190. 190.
    Bassi P, Sacco E, De Marco V, Aragona M, Volpe A. Prognostic accuracy of an artificial neural network in patients undergoing radical cystectomy for bladder cancer: a comparison with logistic regression analysis. BJU Int. 2007;99(5):1007–12.PubMedGoogle Scholar
  191. 191.
    Catto JW, Abbod MF, Linkens DA, Larre S, Rosario DJ, Hamdy FC. Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. Clin Cancer Res. 2009;15(9):3150–5.PubMedGoogle Scholar
  192. 192.
    Catto JW, Linkens DA, Abbod MF, Chen M, Burton JL, Feeley KM, Hamdy FC. Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. Clin Cancer Res. 2003;9(11):4172–7.PubMedGoogle Scholar
  193. 193.
    Qureshi KN, Naguib RN, Hamdy FC, Neal DE, Mellon JK. Neural network analysis of clinicopathological and molecular markers in bladder cancer. J Urol. 2000;163(2):630–3.PubMedGoogle Scholar
  194. 194.
    Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009–18.PubMedGoogle Scholar
  195. 195.
    Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. BJU Int. 2013;111(3 Pt B):E30–6.PubMedGoogle Scholar
  196. 196.
    von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602–8.PubMedGoogle Scholar
  197. 197.
    Sternberg CN, Donat SM, Bellmunt J, Millikan RE, Stadler W, De Mulder P, Sherif A, von der Maase H, Tsukamoto T, Soloway MS. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology. 2007;69(1 Suppl):62–79.PubMedGoogle Scholar
  198. 198.
    Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012;109(6):846–54.PubMedGoogle Scholar
  199. 199.
    Ploeg M, Kums AC, Aben KK, van Lin EN, Smits G, Vergunst H, Viddeleer AC, Geboers AD, van Berkel H, van Boven E, et al. Prognostic factors for survival in patients with recurrence of muscle invasive bladder cancer after treatment with curative intent. Clin Genitourin Cancer. 2011;9(1):14–21.PubMedGoogle Scholar
  200. 200.
    Nakagawa T, Hara T, Kawahara T, Ogata Y, Nakanishi H, Komiyama M, Arai E, Kanai Y, Fujimoto H. Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. J Urol. 2013;189(4):1275–81.PubMedGoogle Scholar
  201. 201.
    Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, et al. Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. World J Urol. 2012;30(6):753–9.PubMedGoogle Scholar
  202. 202.
    Nuhn P, May M, Sun M, Fritsche HM, Brookman-May S, Buchner A, Bolenz C, Moritz R, Herrmann E, Burger M, et al. External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol. 2012;61(1):58–64.PubMedGoogle Scholar
  203. 203.
    Rink M, Shariat SF. Can we apply nomograms derived in the United States to European patients? Yes, we can! Eur Urol. 2012;61(1):65–6.PubMedGoogle Scholar
  204. 204.
    Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17(10):3173–81.PubMedGoogle Scholar
  205. 205.
    Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol. 2012;30(10):1107–13.PubMedCentralPubMedGoogle Scholar
  206. 206.
    De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II—results of EORTC study 3098. J Clin Oncol. 2009;27(33):5634–9.PubMedCentralPubMedGoogle Scholar
  207. 207.
    Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013;105(7):499–503.PubMedCentralPubMedGoogle Scholar
  208. 208.
    Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28(11):1850–5.PubMedGoogle Scholar
  209. 209.
    Niegisch G, Fimmers R, Siener R, Park SI, Albers P. Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur Urol. 2011;60(5):1087–96.PubMedGoogle Scholar
  210. 210.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer. 2013;119(16):3012–9.PubMedGoogle Scholar
  211. 211.
    Kluth LA, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol. 2013. doi:10.1016/j.eururo.2013.11.040Google Scholar
  212. 212.
    Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. BJU Int. 2010;108(5):687–92. doi: 10.1111/j.1464-410X.2010.09902.x. Epub 2010 Nov 19. PMID: 21087453Google Scholar
  213. 213.
    Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, Shariat SF. Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. J Urol. 2011;185(4):1216–21. doi: 10.1016/j.juro.2010.11.082. Epub 2011 Feb 22. PMID: 21334687.Google Scholar
  214. 214.
    Takata, et al. Clin Cancer Res. 2005;11:2625–36.Google Scholar
  215. 215.
    Smith, et al. Lancet Oncol. 2011;12: 137–43.Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Luis A. Kluth
    • 1
    • 2
  • Bernard H. Bochner
    • 3
  • Shahrokh F. Shariat
    • 1
    • 4
    • 5
    Email author
  1. 1.Department of Urology, New York Presbyterian HospitalWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Department of UrologyUniversity Medical-Center Hamburg-EppendorfHamburgGermany
  3. 3.Department of Urology, Memorial Sloan-Kettering Cancer CenterKimmel Center for Prostate and Urologic TumorsNew YorkUSA
  4. 4.Division of Medical Oncology, New York Presbyterian HospitalWeill Cornell Medical CollegeNew YorkUSA
  5. 5.Department of UrologyMedical University of Vienna, WähringerViennaAustria

Personalised recommendations